Stock Price
2.17
Daily Change
-0.18 -7.66%
Monthly
-3.98%
Yearly
69.53%
Q2 Forecast
2.13

Galectin Therapeutics reported $71.74M in Debt for its fiscal quarter ending in December of 2023.





Debt Change Date
AbbVie USD 67.5B 67.5B Dec/2025
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Galectin Therapeutics USD 71.74M 10.6M Dec/2023
Gilead Sciences USD 24.94B 5M Dec/2025
Immunic USD 0 0 Jun/2024
Incyte USD 39.43M 982K Mar/2026
Merck USD 49.34B 7.97B Dec/2025